drug
viltolarsen
Marketedupdated 3mo agoby NS Pharma Inc
Approvedcommunity read0 votes
indications
investigational
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
Trials studying viltolarsen
- phase3Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
- phase2Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)
- phase3Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 12, 2027
358 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Apr 3, 2034compositionUS 9079934
- Aug 31, 2031compositionUS 10870676
FDA exclusivities (1)
- Aug 12, 2027ODE-280Orphan Drug (7y)358d
News(1)
- Capricor CEO won’t rule out legal action against FDA after negative adcommAfter an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior mot…biospace · 17d ago
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that